Former Sen. Ben Sasse Credits Experimental Drug for Shrinking Pancreatic Cancer Tumors

Former U.S. Senator Ben Sasse has shared a rare glimmer of hope in the fight against pancreatic cancer, crediting an experimental drug with shrinking his tumors by 76% and extending his life beyond initial grim projections. Diagnosed with stage 4 metastatic pancreatic cancer in December 2025, Sasse was given just three to four months to live. Today, he attributes his improved condition to daraxonrasib, a clinical trial drug developed by Revolution Medicines, which targets a common genetic mutation in pancreatic cancer patients.

The Drug Behind the “Miracle”

Daraxonrasib is an oral medication designed to target the KRAS gene mutation, which is present in over 90% of pancreatic cancer cases. According to Revolution Medicines, the drug works by inhibiting a specific protein pathway that drives tumor growth. Early clinical trials have shown promise, with some patients experiencing significant tumor reduction and extended survival times.

Sasse, who has been taking daraxonrasib as part of a clinical trial, reported a dramatic improvement in his condition. “I have much less pain than I had four months ago when I was diagnosed and I have a massive 76% reduction in tumor volume over the last four months,” he said during his 60 Minutes interview. While the cancer has spread to his lungs and liver, the drug has allowed him to manage symptoms with less reliance on traditional chemotherapy, which often comes with severe side effects.

How Daraxonrasib Works

Pancreatic cancer is notoriously difficult to treat due to its aggressive nature and resistance to conventional therapies. The KRAS mutation, a key driver of the disease, has long been considered “undruggable” by researchers. However, daraxonrasib represents a recent class of targeted therapies designed to block the mutated KRAS protein, effectively starving the cancer cells of the signals they need to grow.

Unlike chemotherapy, which attacks both healthy and cancerous cells, daraxonrasib is designed to be more precise, potentially reducing side effects like nausea, fatigue, and immune suppression. However, Sasse noted that the drug is not without its challenges. He described experiencing a bleeding skin rash on his face, a known side effect of the treatment.

A Race Against Time

Sasse’s diagnosis came after months of unexplained back and abdominal pain, which he initially attributed to intense triathlon training. By the time doctors confirmed the cancer, it had already metastasized. “Advanced pancreatic is nasty stuff; it’s a death sentence,” he wrote in a December 2025 statement. “But I’m not going down without a fight.”

While daraxonrasib has given him more time, Sasse remains realistic about his prognosis. “Maybe I’m going to crank and live a year instead of a handful of months,” he told 60 Minutes. He also emphasized the role of pain management, noting that morphine has helped alleviate the severe discomfort caused by tumor pressure on his spine.

What This Means for Pancreatic Cancer Patients

Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of just 12%. The disease is often diagnosed at a late stage, when treatment options are limited. However, drugs like daraxonrasib offer new hope for patients who previously had few alternatives.

Revolution Medicines is currently conducting clinical trials to evaluate daraxonrasib’s safety and efficacy. If approved by the U.S. Food and Drug Administration (FDA), the drug could become a standard treatment for patients with KRAS-mutated pancreatic cancer. Early data suggests that patients receiving daraxonrasib may live nearly twice as long as those receiving traditional chemotherapy alone.

Beyond the Diagnosis: Sasse’s Perspective on Life and Legacy

Despite his terminal diagnosis, Sasse has used his platform to reflect on life, faith, and the state of American politics. In his 60 Minutes interview, he described his cancer as “a touch of grace,” forcing him to confront his mortality and prioritize what truly matters. “It’s weird to be in your early 50s and get a terminal diagnosis, and people all of a sudden act like you’re 93 or 94 and you have a lot of wisdom,” he said. “I hate cancer. But I’m also grateful for it. I tell a lot more truth to myself than I used to do when I thought I was super omni-competent and interesting.”

Sasse, who served as a U.S. Senator from Nebraska for eight years and later as president of the University of Florida, has also been vocal about the need for political leaders to focus on long-term challenges rather than short-term partisan battles. “Neither of these parties really have very big or good ideas about 2030 or 2050,” he said. “The Congress is not wrestling with bigger important questions right now.”

Key Takeaways

• Daraxonrasib is an experimental drug targeting the KRAS mutation, present in over 90% of pancreatic cancer cases.
• Former Sen. Ben Sasse reported a 76% reduction in tumor volume after taking the drug as part of a clinical trial.
• The drug offers a more targeted approach than chemotherapy, potentially reducing side effects.
• Pancreatic cancer has a five-year survival rate of just 12%, making new treatments like daraxonrasib critical.
• Sasse’s case highlights the importance of early detection and the potential of precision medicine in treating aggressive cancers.

Frequently Asked Questions

What is daraxonrasib?

Daraxonrasib is an oral drug developed by Revolution Medicines to target the KRAS gene mutation, which drives the growth of many pancreatic cancers. It is currently in clinical trials and has not yet been approved by the FDA.

How effective is daraxonrasib?

Early clinical trials have shown promising results, with some patients experiencing significant tumor shrinkage and extended survival times. However, more research is needed to confirm its long-term efficacy and safety.

What are the side effects of daraxonrasib?

Common side effects include skin rashes, fatigue, and gastrointestinal issues. Sasse reported experiencing a bleeding skin rash on his face while taking the drug.

Is daraxonrasib available to the public?

No. Daraxonrasib is still in clinical trials and is not yet approved for widespread use. Patients interested in participating in trials should consult their oncologist.

What is the survival rate for pancreatic cancer?

The five-year survival rate for pancreatic cancer is approximately 12%, though this varies depending on the stage at diagnosis and the patient’s overall health.

The Road Ahead

Sasse’s story underscores both the devastation of pancreatic cancer and the potential of emerging treatments to change outcomes for patients. While daraxonrasib is not a cure, it represents a significant step forward in the fight against a disease that has long been considered untreatable. As clinical trials continue, researchers and patients alike are watching closely, hopeful that drugs like daraxonrasib will one day transform pancreatic cancer from a death sentence into a manageable condition.

For now, Sasse remains focused on living each day to the fullest. “I’ve got the benefit of this drug,” he said. “I have a lot less tumor pressure on my spine. The combination of a great drug and morphine, another useful drug, I’m in so much less pain now than I was.” His journey serves as a reminder of the urgency of medical innovation—and the resilience of those facing the toughest battles.